Latest News

Developing therapies for cancers harbouring KRAS mutations has proven difficult but PROTACs, acting via targeted protein degradation, may help combat previously undruggable proteins 

Proteomic research on sarcomas is only in its infancy, but it offers potential in terms of improved biological understanding, identification of new treatment targets and generating biomarkers for patient selection and prognosis prediction 

Achieving clarity in levels of clinical evidence required by regulatory bodies is still a major obstacle to expediting research in the field, says Prof. Paolo G. Casali from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and the University of Milan, Italy

Thanks to remarkable advances, molecular analysis has taken central stage in the management of GIST, but there is still a need for less costly testing and further development of mitigation strategies to overcome resistance

2021 ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guidelines open the door to genetic testing but the search for new treatments continues 

Continued efforts in patient selection, combination strategies and novel approaches may help to turn the tide for immunotherapeutics in sarcoma, according to Prof. Jean-Yves Blay 

In practice, doxorubicin alone is often not used as the first-line standard of care for soft tissue sarcomas; however, a lack of high-quality survival data precludes other regimens becoming the gold standard

Tislelizumab in combination with gemcitabine and cisplatin prolonged PFS compared with chemotherapy alone in the RATIONALE 309 study  

Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required 

A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC, but clinical application is still some way off